Press releases

Company will launch the product immediately.

A live webcast and replay of the Tuesday, October 19 conference call will be available.

Registries studied more than 7,000 patients at 236 sites around the globe; results consistent with controlled TAXUS studies.

The results support early safety, which is consistent with results from previous TAXUS clinical trials.

Benefits reported at 12 months were maintained at two years.

The data demonstrated that the safety and efficacy benefits associated with the TAXUS stent system were maintained at two years.

Company will make a special one-time contribution to its U.S. 401(k) Retirement Savings Plan and increase match amounts to six percent of pay.

Subsidiary Advanced Bionics Corporation is voluntarily recalling worldwide all unimplanted CLARION® and HiResolution® cochlear implants.

Together, studies presented will represent more than 10,000 patients.

Galway facility is one of two Company facilities that manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system.

Preliminary worldwide sales of TAXUS systems for the month of August were approximately $200 million.

Registry designed to assess physician usage patterns and evaluate outcome data in "real world" patients.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

A live webcast and replay of the September 1 conference call will be available.

Company will launch the device immediately

Company plans to launch the product in the United States immediately.

Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.

Seattle device company is developing a neurostimulation system whose initial application focused on treating stroke patients.

"We experienced impressive growth across all our businesses and regions," said Jim Tobin, President and Chief Executive Officer.

ATLAS is the first clinical trial using Boston Scientific's new Liberté coronary stent as a platform for its paclitaxel-eluting coronary stent system.

A live webcast and replay of the July 26 conference call will be available.

"Patient safety continues to be our highest priority," said Jim Tobin, President and Chief Executive Officer.

Prospective, multi-center, randomized study designed to evaluate the benefits of filter-based embolic protection during primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI).

The voluntary recall does not affect patients who have already received a TAXUS stent.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Company announces launch of a public offering of $500 million aggregate principal amount of senior notes.

A live webcast and replay of the June 9th conference session will be available.

Company estimates that its share of the U.S. drug-eluting stent market - as of May 31st - continues to be in excess of 70 percent, on a reorder basis.

Acquisition will bring neuromodulation technology, including a range of neurostimulators, programmable drug pumps and cochlear implants.

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

Trial assessed the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics.

Company made the announcement at the annual Paris Course on Revascularization, the largest interventional cardiology conference in Europe.

Company expects to announce 30-day results at the 2004 Transcatheter Cardiovascular Therapeutics conference in September.

A replay of the May 26 analyst meeting will also be available. Learn how to tune into the webcast.

Enteryx found equally effective in controlling GERD symptoms in patients previously treated with proton pump inhibitor (PPI) medications at both standard and high dosing.

Company made the announcement at the annual Digestive Disease Week (DDW) conference.

A live webcast and replay of the May 19 conference session will be available.

"The TAXUS launch continues to go extremely well, with sales growing and execution remaining strong," said Jim Tobin, President and Chief Executive Officer.

Company estimates that its share of the U.S. drug-eluting stent market - as of May 14 - continues to be in excess of 70 percent, on a reorder basis.

A live webcast and replay of the May 6 conference session will be available. Read more.

"This quarter saw the achievement of a major milestone for Boston Scientific with the successful launch of TAXUS in the U.S.," said Jim Tobin, President and CEO.

Combines features from two of Boston Scientific's breakthrough technologies.

(April 14, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2004 on Tuesday, April 20, at 9:00...

(April 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Sentinol™ Self-Expanding Nitinol Biliary Stent System (Sentinol), which has been cleared by...

(April 7, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Precision Vascular Systems, Inc. (Precision Vascular), a privately held company located in West...

(April 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary results related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system and...

(April 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the European Patent Office has declared invalid a patent held by Medinol Ltd. This is the patent that Boston...

(March 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has concluded enrollment in its TAXUS V de novo lesion clinical trial. The Company has enrolled 1,172...

(March 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Contour SE™...

(March 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) and EndoTex Interventional Systems, Inc. announced today the completion of enrollment in a carotid artery stenting clinical trial to...